Related Experiment Video

Updated: Nov 1, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.0K

[New Treatment Strategies for BRAF Mutation-Positive Colorectal Cancer]

Hisato Kawakami1, Sota Ogata

  • 1Dept. of Medical Oncology, Kindai University Faculty of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 17, 2021
PubMed

Insights

Precision medicine offers new hope for BRAF-mutated colorectal cancer. The BEACON CRC study shows promising results for a combination therapy targeting BRAF V600E mutations.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Precision medicine is emerging in colorectal cancer treatment, focusing on tumor genetics.
  • BRAF mutations in colorectal cancer (CRC) historically lacked targeted therapies, leading to poor prognoses with standard chemotherapy.
  • Recent advancements enable targeted treatments for BRAF-mutated CRC.

Purpose of the Study:

  • To review the characteristics, development, and novel treatment strategies for BRAF-mutated colorectal cancer.
  • To introduce the BEACON CRC study evaluating a combination therapy for BRAF V600E-mutated metastatic colorectal cancer.

Main Methods:

  • Review of current literature on BRAF-mutated colorectal cancer.
  • Prospective evaluation of a combination therapy including encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (anti-EGFR antibody) in the BEACON CRC study.

Main Results:

  • Conventional chemotherapy shows limited efficacy in BRAF-mutated CRC.
  • The BEACON CRC study investigated the efficacy and safety of the combination therapy in patients with BRAF V600E-mutated metastatic colorectal cancer.

Conclusions:

  • New drugs targeting BRAF mutations are crucial for improving outcomes in colorectal cancer.
  • Combination therapy with BRAF, MEK, and EGFR inhibitors represents a promising new strategy for BRAF-mutated metastatic colorectal cancer.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.3K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
790
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K